IPOpulse
Back to Ticker

Jubilant Pharmova Limited

NSE: JUBLPHARMA
Healthcare Healthcare
₹935.8
-0.30%EOD · 19 Oct

Jubilant Pharmova Limited is a listed Healthcare company on NSE/BSE. Detailed profile data is being compiled — check BSE filings for the latest disclosures.

Market Cap
₹14,822 Cr
52W Range
₹1185 / ₹786
Volume
81K
55.0% delivery
1Y Return
-16.8%
P/E Ratio
42.3
P/B Ratio
2.1
ROE
6.0%
Debt / Equity
50.94

Peers in Healthcare

Top 8 by market cap
CompanyLTP30DMarket CapP/EP/BROE %Div Yld %
Jubilant Pharmova Limited(this stock)₹935.8₹14,822 Cr42.32.16.0%0.53%
Divi's Laboratories LimitedDIVISLAB₹9,087₹2.41 L Cr83.014.516.2%0.33%
Torrent Pharmaceuticals LimitedTORNTPHARM₹4,558.7₹1.73 L Cr72.818.417.0%0.83%
Laurus Labs LimitedLAURUSLABS₹2,069₹1.12 L Cr101.821.017.7%0.12%
Zydus Lifesciences LimitedZYDUSLIFE₹1,113.9₹1.11 L Cr25.04.218.3%0.09%
Apollo Hospitals Enterprise LimitedAPOLLOHOSP₹7,700₹1.11 L Cr54.312.021.5%0.25%
Aurobindo Pharma LimitedAUROPHARMA₹1,621.4₹93,292 Cr26.12.69.9%0.00%
Mankind Pharma LimitedMANKIND₹2,253.2₹93,067 Cr46.05.812.4%0.00%
Max Healthcare Institute LimitedMAXHEALTH₹830₹80,785 Cr56.77.714.3%0.23%

Quality Score

Durability · Valuation · Momentum — objective math, not advice
D
28/100
Composite score: 40% quality, 30% valuation, 30% momentum
QualityWeak · 35
ValuationAverage · 43
MomentumPoor · 5
High debt load (D/E 50.9)
In confirmed downtrend (Stage 4)

Technical Indicators

Full analysis · objective math, not advice
Returns
1D
-0.3%
1W
-1.6%
1M
-7.5%
3M
-8.6%
6M
+2.7%
1Y
-16.8%
Weinstein Stage
Stage 4 — Declining (downtrend)
RSI (14)
15 Oversold
Trend Template
1/7weak
RS vs Nifty (3M)
-2.6pp
Moving Averages (price vs MA)
20-DMA
₹995
below
50-DMA
₹957
below
150-DMA
₹949
below
200-DMA
₹950
below
From 52W High
-21.0%
From 52W Low
+19.1%
Support (20D)
₹908
Resistance (20D)
₹1092

Technical indicators are objective calculations from historical EOD prices (RSI, moving averages, Weinstein stage, Minervini trend-template, relative strength). For educational reference only — not a buy/sell recommendation.

Community discussion(0)

Sign in to join the discussion.

Sign in

No comments yet — be the first to share your view.